CLV IntelligenceReimbursement Policy Monitoring

Code intelligence

LCD-L40226 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code LCD-L40226.

Critical code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Critical
1

Critical

100%

0

High

0%

0

Routine

0%

0

Low

0%

New this month

+1

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

LCD L40226: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in Cancer — CGS

Policy LCD-L40226 · Oncology

Critical

This final LCD from CGS (J15) establishes coverage criteria for non-next generation sequencing targeted molecular panel tests used to guide targeted therapy decisions in cancer patients in Kentucky an

View alert

Audit documentation

Building an audit file that includes LCD-L40226?

The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Oncology audit pack — $349One-time purchase · not a subscription